FACULTY
Getting To Goal: Effective Control Of Hypertension
Paper Symposium
Activity Date: June 2005  — Activity Info: Volume 5, (6B)
Goals & Objectives | Faculty | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired) | Order Copy of Activity

 

Full Disclosure Policy Affecting CME Activities:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:

PROGRAM DIRECTOR

Roger S. Blumenthal, MD
Associate Professor of Medicine
Department of MedicineÐCardiovascular
Johns Hopkins Ciccarone Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr Blumenthal reports receiving grants/research support and occasional honoraria from AstraZeneca, KOS Pharmaceuticals Inc, Merck and Company, Pfizer Inc, and  Wyeth Pharmaceuticals over the past 3 years.

PARTICIPATING FACULTY

Joseph L. Izzo, Jr, MD
Professor of Medicine
SUNY
Buffalo, New York
Dr Izzo reports receiving grants/research support from Alteon, GlaxoSmithKline, Novartis, Omron, Pfizer Inc, and Sankyo Pharma; serving as a consultant for Alteon, AstraZeneca, GlaxoSmithKline, Intercure, Merck and Company, Novartis, Omron, and Sankyo Pharma; and serving on the speakerÕs bureau for AstraZeneca, Biovail, Boehringer-Ingelheim, Merck and Company, Novartis, Pfizer Inc, and Sankyo Pharma.

C. Venkata S. Ram, MD, FACC, MACP
Director, Texas Blood Pressure Institute
Dallas Nephrology Associates
Clinical Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas
Dr Ram reports serving as a consultant or on the speakerÕs bureau for Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Elan Corporation, Eon Labs Inc, Forest Laboratories Inc, King Pharmaceuticals Inc, KOS Pharmaceuticals Inc, Knoll Inc, Merck and Company, Novartis, Pfizer Inc, Pharmacia Corporation, Reliant Pharmaceuticals, Roche, Sankyo Pharma, Sanofi-Synthelabo US, Searle/Monsanto Company, Solvay Pharmaceuticals Inc, Unimed Pharmaceuticals Inc, Wellspring Pharmaceuticals, and Wyeth Pharmaceuticals.

Notice: The authors have indicated that this CE activity contains no mention of unlabeled/unapproved uses of drugs or devices.

Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

     
Home | Contact Us | View Account | Need Help?